ORIC Q4 2025 Earnings — ORIC Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ORICORIC Pharmaceuticals, Inc.

$1B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$320,000

Operating Income

-$35M

Net Income

-$31M

EPS (Diluted)

$-0.30

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$22M

Free Cash Flow

-$23M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$411M

Total Liabilities

$27M

Stockholders' Equity

$384M

Cash & Equivalents

$46M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$320,000	-$304,000	-5.3%
Operating Income	-$35M	-$40M	+12.7%
Net Income	-$31M	-$36M	+16.0%